Bone marrow mesenchymal stem cell treatment for myocardial ischemia/reperfusion injury: mechanisms of exosomes and factors
10.3969/j.issn.2095-4344.1599
- VernacularTitle:骨髓间充质干细胞治疗心肌缺血再灌注损伤:外泌体及因子的作用机制
- Author:
Changjiang ZHANG
1
;
Guiyou LIANG
Author Information
1. 遵义医学院附属医院心血管外科
- Keywords:
Bone Marrow;
Mesenchymal Stem Cells;
Myocardial Ischemia;
Reperfusion Injury;
Tissue Engineering
- From:
Chinese Journal of Tissue Engineering Research
2019;23(12):1455-1460
- CountryChina
- Language:Chinese
-
Abstract:
BACKGROUND: Myocardial ischemia/reperfusion injury is one of the most common complications in ischemic cardiomyopathy and open heart surgery. The development of bone marrow mesenchymal stem cells provides a new method for clinical prevention and treatment of myocardial ischemia/reperfusion injury. OBJECTIVE: To review the therapeutic effect and potential mechanisms of bone marrow mesenchymal stem cells in the treatment of myocardial ischemia/reperfusion injury, in order to provide a theoretical basis for the clinical application of bone marrow mesenchymal stem cells. METHODS: Chinese Journal Full-text Database (CNKI) , WanFang, and PubMed were retrieved for articles related to the use of bone marrow mesenchymal stem cells for myocardial ischemia-reperfusion injury published from January 2000 to October 2018. The search terms were "bone marrow mesenchymal stem cells; myocardial ischaemia/reperfusion; research process" in Chinese and "bone marrow mesenchymal stem cells; myocardial ischaemia/reperfusion; cell therapy; clinical trial studies" in English. Old and repetitive viewpoints were excluded, the searched literatures were sorted out, and finally 56 articles were included for further analysis and discussion. RESULTS AND CONCLUSION: (1) In this paper, we summarize paracrine factors, exosomes miRNA and their effects in the treatment of myocardial ischemia/reperfusion injury with bone marrow mesenchymal stem cells, such as anti-inflammation, anti-apoptosis, anti-fibrosis, repair of myocardium and neovascularization. (2) We also summarize the possible molecular mechanisms of bone marrow mesenchymal stem cells involved in the treatment of myocardial ischemia/reperfusion injury, such as the role of mitochondrial fusion protein 2, regulation of myocardial autophagy, and regulation of AMPK/mTOR signaling pathway. Overall, we attempt to provide a theoretical basis for the clinical application of bone marrow mesenchymal stem cells in the treatment of myocardial ischemia/reperfusion injury.
